Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
0.9431
+0.1007 (11.95%)
Nov 13, 2026, 4:00 PM EST - Market closed
Perspective Therapeutics Revenue
Perspective Therapeutics had revenue of $20.00K in the quarter ending September 30, 2026, a decrease of -90.43%. This brings the company's total for the last twelve months to $220.00K, down -79.53% year-over-year. In the year 2025, Perspective Therapeutics had annual revenue of $884.00K, down -39.20%. That makes Perspective Therapeutics the 45,403rd largest company in the world by revenue and 6,592nd in the United States.
Revenue (ttm)
$220.00K
Revenue Growth
-79.53%
P/S Ratio
517.67
Revenue / Employee
$1,325
Employees
166
Market Cap
113.89M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 884.00K | -570.00K | -39.20% |
| Dec 31, 2024 | 1.45M | 20.00K | 1.39% |
| Dec 31, 2023 | 1.43M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | 10.05M | 373.00K | 3.85% |
| Jun 30, 2020 | 9.68M | 2.37M | 32.35% |
| Jun 30, 2019 | 7.31M | 1.39M | 23.48% |
| Jun 30, 2018 | 5.92M | 1.16M | 24.41% |
| Jun 30, 2017 | 4.76M | -8.00K | -0.17% |
| Jun 30, 2016 | 4.77M | 163.00K | 3.54% |
| Jun 30, 2015 | 4.61M | 386.84K | 9.17% |
| Jun 30, 2014 | 4.22M | -306.08K | -6.76% |
| Jun 30, 2013 | 4.53M | -545.86K | -10.76% |
| Jun 30, 2012 | 5.07M | -167.89K | -3.20% |
| Jun 30, 2011 | 5.24M | -47.11K | -0.89% |
| Jun 30, 2010 | 5.29M | -131.73K | -2.43% |
| Jun 30, 2009 | 5.42M | -1.74M | -24.32% |
| Jun 30, 2008 | 7.16M | 1.42M | 24.76% |
| Jun 30, 2007 | 5.74M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Neuronetics | 159.76M |
| Outset Medical | 121.97M |
| Owlet | 114.41M |
| Pulmonx | 88.78M |
| Apyx Medical | 59.57M |
| TriSalus Life Sciences | 46.39M |
| MaxCyte | 34.37M |
| Nyxoah | 32.77M |
CATX News
- 1 day ago - Perspective Therapeutics price target lowered to $1 from $5 at BofA - TheFly
- 4 days ago - Perspective Therapeutics reports Q3 EPS (27c), consensus (25c) - TheFly
- 4 days ago - Perspective Therapeutics price target lowered to $8 from $14 at Piper Sandler - TheFly
- 4 days ago - Perspective Therapeutics price target lowered to $8 from $11 at Truist - TheFly
- 5 days ago - Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results - GlobeNewsWire
- 5 days ago - Perspective Therapeutics Earnings release: Q3 2026 - Filings
- 5 days ago - Perspective Therapeutics Quarterly report: Q3 2026 - Filings
- 8 days ago - Perspective Therapeutics presents VMT01 monotherapy data from Phase 1/2a study - TheFly